新型冠状病毒奥密克戎BA.4/5和BA.2.12.1亚变体的中和作用 - Suppr

Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants.

作者信息

Qu Panke, Faraone Julia, Evans John P, Zou Xue, Zheng Yi-Min, Carlin Claire, Bednash Joseph S, Lozanski Gerard, Mallampalli Rama K, Saif Linda J, Oltz Eugene M, Mohler Peter J, Gumina Richard J, Liu Shan-Lu

机构信息

Ohio State University, Columbus, OH

出版信息

N Engl J Med. 2022 Jun 30;386(26):2526-2528. doi: 10.1056/NEJMc2206725. Epub 2022 Jun 15.

DOI:10.1056/NEJMc2206725

PMID:35704428

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9258774/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f7bc/9258774/7fe9aa1c248a/NEJMc2206725_f1.jpg

相似文献

Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants.

N Engl J Med. 2022 Jun 30;386(26):2526-2528. doi: 10.1056/NEJMc2206725. Epub 2022 Jun 15.

Neutralization Escape by SARS-CoV-2 Omicron Subvariant BA.4.6.

N Engl J Med. 2022 Nov 17;387(20):1904-1906. doi: 10.1056/NEJMc2212117. Epub 2022 Oct 19.

Protective Effect of Previous SARS-CoV-2 Infection against Omicron BA.4 and BA.5 Subvariants.

N Engl J Med. 2022 Oct 27;387(17):1620-1622. doi: 10.1056/NEJMc2209306. Epub 2022 Oct 5.

Spike Protein Antibodies Mediate the Apparent Correlation between SARS-CoV-2 Nucleocapsid Antibodies and Neutralization Test Results.

Microbiol Spectr. 2021 Sep 3;9(1):e0021821. doi: 10.1128/Spectrum.00218-21. Epub 2021 Jun 16.

Neutralization of the SARS-CoV-2 Deltacron and BA.3 Variants.

N Engl J Med. 2022 Jun 16;386(24):2340-2342. doi: 10.1056/NEJMc2205019. Epub 2022 May 18.

Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5.

N Engl J Med. 2022 Jul 7;387(1):86-88. doi: 10.1056/NEJMc2206576. Epub 2022 Jun 22.

Characterization of Entry Pathways, Species-Specific Angiotensin-Converting Enzyme 2 Residues Determining Entry, and Antibody Neutralization Evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 Variants.

J Virol. 2022 Sep 14;96(17):e0114022. doi: 10.1128/jvi.01140-22. Epub 2022 Aug 24.

Neutralization of SARS-CoV-2 Omicron BA.2.75 after mRNA-1273 Vaccination.

N Engl J Med. 2022 Sep 29;387(13):1234-1236. doi: 10.1056/NEJMc2210648. Epub 2022 Sep 9.

Different Neutralization Profiles After Primary SARS-CoV-2 Omicron BA.1 and BA.2 Infections.

Front Immunol. 2022 Jul 19;13:946318. doi: 10.3389/fimmu.2022.946318. eCollection 2022.

Emerging Omicron subvariants evade neutralizing immunity elicited by vaccine or BA.1/BA.2 infection.

J Med Virol. 2023 Feb;95(2):e28539. doi: 10.1002/jmv.28539.

引用本文的文献

Efficacy and safety of a novel multivalent mRNA vaccine against SARS-CoV-2 in experimental animals.

Sci Rep. 2025 Jul 1;15(1):21831. doi: 10.1038/s41598-025-07661-8.

Predominant T-cell epitopes of SARS-CoV-2 restricted by multiple prevalent HLA-B and HLA-C allotypes in Northeast Asia.

Front Immunol. 2025 May 21;16:1545510. doi: 10.3389/fimmu.2025.1545510. eCollection 2025.

Making Universal Vaccines and Antibodies Through Glycoengineering.

Methods Mol Biol. 2025;2926:35-50. doi: 10.1007/978-1-0716-4542-0_3.

A global collaboration for systematic analysis of broad-ranging antibodies against the SARS-CoV-2 spike protein.

Cell Rep. 2025 Apr 22;44(4):115499. doi: 10.1016/j.celrep.2025.115499. Epub 2025 Apr 2.

Post-Pandemic Perspectives: Willingness, Risk Perception and Factors Influencing COVID-19 Booster Vaccine Uptake Among Thai Healthcare Workers and Vulnerable Populations.

Vaccines (Basel). 2024 Dec 7;12(12):1381. doi: 10.3390/vaccines12121381.

The Anti-SARS-CoV-2 S-Protein IgG, Which Is Detected Using the Chemiluminescence Microparticle Immunoassay (CMIA) in Individuals Having Either a History of COVID-19 Vaccination and/or SARS-CoV-2 Infection, Showed a High-Titer Neutralizing Effect.

Viruses. 2024 Sep 3;16(9):1409. doi: 10.3390/v16091409.

Computationally designed Spike antigens induce neutralising responses against the breadth of SARS-COV-2 variants.

NPJ Vaccines. 2024 Sep 9;9(1):164. doi: 10.1038/s41541-024-00950-9.

Science-based exit from stringent countermeasures against COVID-19: Mortality prediction using immune landscape between 2021 and 2022 in Japan.

Vaccine X. 2024 Aug 12;20:100547. doi: 10.1016/j.jvacx.2024.100547. eCollection 2024 Oct.

Three SARS-CoV-2 spike protein variants delivered intranasally by measles and mumps vaccines are broadly protective.

Nat Commun. 2024 Jul 3;15(1):5589. doi: 10.1038/s41467-024-49443-2.

SARS-CoV-2 BA.4/5 infection triggers more cross-reactive FcγRIIIa signaling and neutralization than BA.1, in the context of hybrid immunity.

J Virol. 2024 Jul 23;98(7):e0067824. doi: 10.1128/jvi.00678-24. Epub 2024 Jul 2.

本文引用的文献

Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2.

Cell Host Microbe. 2022 Aug 10;30(8):1093-1102.e3. doi: 10.1016/j.chom.2022.04.014. Epub 2022 Apr 25.

SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination.

N Engl J Med. 2022 Mar 17;386(11):1088-1091. doi: 10.1056/NEJMc2119912. Epub 2022 Jan 26.

Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers, and convalescent plasma donors.

JCI Insight. 2020 Nov 19;5(22):143213. doi: 10.1172/jci.insight.143213.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献